ADC

Africa Digital Clinic

Disease prevention, early detection and effective management.

Adco Salterpyn Syrup: Embrace Comfort and Relief for Pain and Fever

Table of Contents

Relieve discomfort with Adco Salterpyn Syrup. The effective formula offers fast relief from pain and discomfort, making it an ideal choice for easing various ailments. Discover the soothing power of Adco Salterpyn Syrup today.

Adco Salterpyn Syrup Is Used For

For the relief of mild to moderate pain, associated with fever.

Dosage

2 to 5 years: One medicine-measure (5 ml) three times a day, 6 to 12 years: One to two medicine-measures (5 to 10 ml) three times a day.

How To Take

Do not share medicines prescribed for you with any other person.

What Adco Salterpyn Syrup Contains

Codeine phosphate 5 mg, promethazine hydrochloride 6.5 mg, paracetamol 120 mg.

Other Ingredients
Preservatives: Methyl hydroxybenzoate 0.10 % m/v, propyl hydroxybenzoate 0.01 % m/v. Contains alcohol: 12.5 %  v/v.

Contains sugar: Sucrose 1.10 g, liquid glucose 2.0 g, invert syrup 600 mg.

Therapeutic Classification
Opioids in combination with non-opioid analgesics.

 

Adco Salterpyn Syrup
Adco Salterpyn Syrup

 

COMPOSITION:

Each 5 ml of syrup contains:

Codeine phosphate 5 mg
Promethazine hydrochloride 6,5 mg
Paracetamol 120 mg

Preservatives:
Methyl hydroxybenzoate 0, 10 % m/v
Propyl hydroxybenzoate 0,01 % m/v
Contains alcohol: 12,5 % v/v

Contains sugar:
Sucrose 1 , 1 0 g
Liquid glucose 2,0 g
Invert syrup 600 mg

PHARMACOLOGICAL CLASSIFICATION:

A 2.8 Special analgesic combinations

PHARMACOLOGICAL ACTION:

ADCO-SAL TERPYN® SYRUP has analgesic, antipyretic and antihistaminic properties.

INDICATIONS:
For the relief of mild to moderate pain, associated with fever.

CONTRAINDICATIONS:
Sensitivity to paracetamol, opiates or phenothiazines
Contraindicated in children under 2 years of age.

WARNINGS AND SPECIAL PRECAUTIONS:

This product contains paracetamol which may be fatal in overdose. In the event of overdosage or suspected overdose and notwithstanding the fact that the person may be asymptomatic, the nearest doctor, hospital or Poison Centre must be contacted immediately.

Dosages in excess of those recommended may cause severe liver damage.

If the patient does not respond, a doctor should be consulted.
Do not use continuously for more than 10 days without consulting a doctor.
This medicine may cause drowsiness and impaired concentration that may be aggravated by simultaneous intake of alcohol or other central nervous system depressants.

Pigments should be examined periodically for abnormal skin pigmentation or eye changes.

Codeine: Exceeding the prescribed dose, together with prolonged and continuous use of this medication, may lead to dependency and addiction.
Do not administer to patients with liver or kidney damage. If taken in excess, this medicine may cause liver damage which may be fatal.

Large doses of promethazine may precipitate fits in epileptics.
Serious life-threatening cases of respiratory depression, including fatalities have been reported with promethazine use in paediatric patients less than 2 years of age.

Contains sucrose and glucose which may have an effect on the glycaemic control of patients with diabetes mellitus. Contains sucrose. Patients with rare hereditary conditions such as fructose intolerance, glucose-galactose mal-absorption or sucrase-isomaltase insufficiency should not take ADCO-SAL TERPYN SYRUP.

DOSAGE AND DIRECTIONS FOR USE:

DO NOT EXCEED THE RECOMMENDED DOSE.

2 to 5 years: One medicine-measure (5 ml) three times a day
6 to 12 years: One to two medicine-measures (5 to 10 ml) three times a day.

SIDE EFFECTS

Frequency classes: Very common(> 1/10); common(> 1/100, < 1/10);
uncommon(> 1/1000, < 1/100); rare(> 1/10 000, < 1/1 000); very rare(< 1/10 000).

Codeine

Immune system disorders:
Less frequent: Urticaria.

Psychiatric disorders:
Frequency unknown: Mental clouding and dysphoria.

Vascular disorders:
Less frequent or rare: Dizziness.

Gastrointestinal disorders:
More frequent: Constipation.
Less frequent: Nausea and vomiting.

Hepatobiliary disorders:
Frequency unknown: Increased pressure in the biliary tract.

Skin and subcutaneous tissue disorders:
Less frequent: Skin rash.

Promethazine

Blood and lymphatic system disorders:
Frequency unknown: Thrombocytopenia purpura and agranulocytosis.
Less frequent or rare: Blood dyscrasias and haemolytic anaemia.

Immune system disorders:
Frequency unknown: Allergic reactions, idiosyncrasy and lupus erythematous-like syndrome.

Metabolism and nutrition disorders:
Less frequent or rare: Anorexia.

Psychiatric disorders:
Less frequent or rare: Irritability and restlessness.
Frequency unknown: Depression, elation, hallucinations and insomnia.

Nervous system disorders:
Less frequent: Blurred vision.
Frequency unknown: Muscular weakness, headache, tinnitus, extrapyramidal dysfunction and incoordination.

Eye disorders:
Frequency unknown: Deposition of pigment in the eyes, corneal and lens opacities.

Cardiac disorders:
Less frequent or rare: Increase in heart rate.

Vascular disorders:
Less frequent or rare: Hypotension and dizziness.

Respiratory, thoracic and mediastinal disorders:
Frequency unknown: Tightness of chest.

Gastrointestinal disorders:
Frequency unknown: Nausea, vomiting, colic or epigastric pain and diarrhoea or constipation.
Less frequent or rare: Dryness of the mouth.

Hepatobiliary disorders:
Frequency unknown: Jaundice of the obstructive type.

Skin and subcutaneous tissue disorders:
Less frequent or rare: Photosensitivity and skin rash.

Musculoskeletal and connective tissue disorders:
Frequency unknown: Weakness of hands.

Renal and urinary disorders:
Less frequent: Difficulty in micturition.
Frequency unknown: Polyuria.

General disorders and administration site conditions:
Frequency unknown: Lassitude, tiredness, weakness, lowering of blood temperature and pyrexia.

Paracetamol

Blood and lymphatic system disorders:
Frequency unknown: Leucopenia, pancytopenia and neutropenia.

Immune system disorders:
Frequency rare: Allergic reactions.

Gastrointestinal disorders:
Frequency unknown: Pancreatitis.

Skin and subcutaneous tissue disorders:
Rare: Skin rash (usually erythematous or urticaria!).
Frequency unknown: Mucosa! lesions.

General disorders and administration site conditions:
Frequency unknown: Drug fever.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

Codeine:

Symptoms of overdosage with codeine phosphate include nausea, vomiting and drowsiness or coma and respiratory collapse.
In acute poisoning with codeine phosphate, the stomach should be emptied by aspiration and lavage.
Intensive supportive therapy may be necessary to correct respiratory failure and shock. The specific antagonist naloxone may be used to counteract severe respiratory depression.

Promethazine:

Promethazine overdosage may be fatal, especially in infants and children in whom main symptoms are central nervous system stimulation and antimuscarinic effects including ataxia, excitement, hallucinations, hyperpyrexia and respiratory collapse.

Death may occur from respiratory failure.
Drowsiness and hypotension may occur.

Treatment is symptomatic and supportive.

Paracetamol:

Prompt treatment is essential. In the event of an overdosage, consult a doctor immediately, or take the person directly to a hospital. A delay in starting treatment may mean that antidote is given too late to be effective.

Evidence of liver damage is often delayed until after the time for effective treatment
has lapsed.

Susceptibility to paracetamol toxicity is increased in patients who have taken repeated high doses (greater than 5 -10 g/day) of paracetamol for several days, in chronic alcoholism, chronic liver disease, AIDS, malnutrition, and with the use of drugs that induce liver microsomal oxidation such as barbiturates, isoniazid, rifampicin, phenytoin and carbamazepine.

Symptoms of paracetamol overdosage in the first 24 hours include pallor, nausea, vomiting, anorexia and possibly abdominal pain. Mild symptoms during the first two days of acute poisoning, do not reflect the potential seriousness of the overdosage.

Liver damage may become apparent 12 to 48 hours, or later after ingestion, initially by elevation of the serum transaminase and lactic dehydrogenase activity, increased serum bilirubin concentration and prolongation of the prothrombin time. Liver damage may lead to encephalopathy, coma and death.

Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Abnormalities of glucose metabolism and metabolic acidosis may occur. Cardiac arrhythmias have been reported.

Treatment for paracetamol overdosage: Although evidence is limited it is recommended that any adult person who has ingested 5 – 10 grams or more of paracetamol ( or a child who has had more than 140 mg/kg) within the preceding four hours, should have the stomach emptied by lavage (emesis may be adequate for children) and a single dose of 50 g activated charcoal given via the lavage tube.

Ingestion of amounts of paracetamol smaller than this may require treatment in patients susceptible to paracetamol poisoning (see above). In patients who are stuperose or comatose endotracheal intubation should precede gastric lavage in order to avoid aspiration.

N-acetylcysteine should be administered to all cases of suspected overdose as soon as possible preferably within eight hours of overdosage, although treatment up to 36 hours after ingestion may still be of benefit, especially if more than 150 mg/kg of paracetamol was taken. An initial dose of 150 mg/kg N-acetylcysteine in 200 ml dextrose injection given intravenously over 15 minutes, followed by an infusion of 50 mg/kg in 500 ml dextrose injection over the next four hours, and then 100 mg/kg in 1 000 ml dextrose injection over the next sixteen hours. The volume of intravenous fluid should be modified for children.

Although the oral formulation is not the treatment of choice, 140 mg/kg dissolved in water may be administered initially, followed by 70 mg/kg every four hours for seventeen doses.

A plasma paracetamol level should be determined four hours after ingestion in all cases of suspected overdosage. Levels done before four hours may be misleading. Patients at risk of liver damage, and hence requiring continued treatment with N-acetylcysteine, can be identified according to their 4-hour plasma paracetamol level.

The plasma paracetamol level can be plotted against time since ingestion in the nomogram. The nomogram should be used only in relation to a single acute ingestion.

Those whose plasma paracetamol levels are above the “normal treatment line”, should continue Nacetylcysteine treatment with 100 mg/kg IV over sixteen hours repeatedly until recovery. Patients with increased susceptibility to liver damage as identified above, should continue treatment if concentrations are above the “high risk treatment line”. Prothrombin index correlates best with survival.
Monitor all patients with significant ingestions for at least ninety-six hours.

error: Content is protected !!